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Recombinant antibody cloning and phage display technologies can be 
employed to produce and isolate single-chain antibodies (scFv) specifically 
against antigen of interest. The aims of this study are to construct single chain 
variable fragment (scFv) towards MCF-7 breast cancer cells and to 
characterize scFv antibodies that interacts with MCF-7. Initially, mRNA was 
extracted from previously well-characterized monoclonal antibody (C3A8) 
against MCF-7. The genes encoding heavy (VH) and light (VL) chains were 
amplified, linked in VH-VL orientation via PCR and cloned into a pCANTAB 
5E phagemid vector. The protein was then expressed in a supE strain of E. coli 
TG1. Phage particles displaying scFv were panned against MCF-7 and the 
selected clones were further used for infecting non-suppressor strain, E. coli 
HB2151. The scFv antibodies expressed were characterized by enzyme-linked 
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immunosorbent assay (ELISA) and immunoblotting. As demonstrated by 
ELISA result, the scFv antibodies could strongly bind to MCF-7 breast cancer 
cells. It retained the binding capacity of its parental C3A8 monoclonal 
antibody. Clone B7 was expressed mainly as soluble periplasmic protein. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis of the recombinant antibody revealed a protein with apparent 
molecular weight of approximately 32 kDa. Nucleotide sequence analysis of 
C3A8 scFv showed high homology (99%) with published single chain 
antibody against rice stripe virus protein P20 [synthetic construct]. In 
conclusion, the recombinant antibody technology is an effective approach in 
the development of scFv antibody for the next generation of immunotherapy 
reagents especially towards MCF-7 breast cancer cells. 
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Pengklonan antibodi rekombinan dan teknologi pameran faj digunakan bagi 
menghasilkan dan memencilkan satu rantaian serpihan boleh ubah (scFv) 
antibodi secara spesifik terhadap sebarang antigen yang diminati. Objektif 
kajian adalah untuk membina satu rantaian serpihan boleh ubah (scFv) 
antibodi terhadap sel kanser payu dara (MCF-7). Sebagai permulaan, mRNA 
(pengutus RNA) diekstrak daripada hybridoma (C3A8) yang sebelum ini telah 
berjaya dicirikan sifatnya dalam menghasilkan monoklonal antibodi (Mab) 
terhadap MCF-7. Gen-gen yang mengkodkan rantaian berat (VH)  dan ringan  
(VL) diamplifikasikan, disambungkan pada orientasi VH-VL melalui 
tindakbalas PCR dan diklonkan ke dalam vector  fajmid pCANTAB 5E. 
Protein kemudiannya diekspreskan di dalam strain penindas E. coli TG1. 
Partikel-partikel faj yag mempamerkan scFv dilimpahkan ke atas MCF-7 dan 
klon-klon terpilih kemudiannya digunakan bagi menjangkiti strain tanpa 
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penindas, E. coli HB 2151. Antibodi scFv yang diekspreskan selanjutnya 
dicirikan melalui ujian ELISA dan immunopemblotan. Sepertimana yang 
didemonstrasikan oleh keputusan ELISA, antibodi scFv berupaya untuk 
mengikat secara kuat kepada sel kanser payu dara, MCF-7. Ianya dapat 
mengekalkan keupayaan mengikat yang sama seperti Mab yang asal (C3A8). 
Kebanyakan klon B7 mengekspreskan scFv antibodinya dalam bentuk protein 
periplasmik terlarut. Analisis elektroforesis gel SDS-PAGE ke atas antibodi 
rekombinan jelas menunjukkan protein yang bersaiz 32 kDa berjaya 
diekspreskan. Analisis penjujukan DNA bagi scFv C3A8 pula memberikan 
tahap persamaan yang tinggi (99%) dengan satu rantaian serpihan boleh ubah 
(scFv) antibodi terhadap protein virus berjalur beras, P20 (pembinaan 
sintetik). Secara keseluruhannya, teknologi antibodi rekombinan adalah 
merupakan satu pendekatan berkesan di dalam pembinaan antibodi scFv di 
mana ia juga berpotensi bagi perkembangan reagen immunoterapi untuk 
generasi yang akan datang terutamanya terhadap sel kanser payu dara, MCF-7. 
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CHAPTER I 
 
INTRODUCTION 
 
Beginning in 1975, monoclonal antibodies (Mabs) have been favored as they 
can be produced in unlimited quantities to practically bind to any antigen and 
are more easily standardized. However, there are limitations to their clinical 
applications, as they are almost exclusively murine in origin which could 
create human anti-mouse response (HAMA) when introduced to human 
(Klimka et al., 2000). The monoclonal antibody producing antibody 
technology is also very laborious and time consuming and small mammals like 
mice do not always provide the high-affinity antibody response to particular 
antigen needed for sensitive assay development (O'Connor et al., 1997). These 
limitations of traditional techniques have led several research groups to 
investigate the use of phage display in producing single chain Fv (scFv) 
antibodies.  
 
The generation of scFv has now become an established technique used to 
produce a completely functional antigen-binding fragment in bacterial 
systems. The variable fragment (Fv) portion of an antibody, consisting of 
variable heavy chain (VH) and variable light chain (VL) domains is the 
smallest fragment that consistently maintains the binding specificity and 
affinity of the whole antibody (Glockshuber et al., 1990). Previously, active 
Fv fragments have been produced by proteolytic digestion of the antibody 
molecule (Hochman et al., 1973). However, the proteolysis often does not 
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result in a homogenous population of Fv fragments but rather produces a 
number of partially digested protein molecule, which may cause difficulties in 
both purification and characterization. Therefore, the advances in antibody 
engineering have now facilitated a more efficient and generally applicable 
method to produce Fv fragments. Nevertheless, the utility of the Fv fragments 
is limited by disassociation of the variable domains at low protein 
concentrations and in the absence of antigen (Glockshuber et al., 1990; Jager 
and Pluckthun, 1999). 
 
 The recombinant scFv construction represents a further technological advance 
in stabilized Fv production by means of joining both of VL and VH domains 
covalently into a single polypeptide chain (~30 kDa in size) using an 
engineered flexible polypeptide linker (Bird et al., 1988). The designed linker 
used should also be stable against proteolysis and should minimize protein 
aggregation, in addition to contributing to scFv solubility (Whitlow et al., 
1993). For these reasons, an established flexible peptide linker, (Gly4Ser)3,  
was chose in this study for bridging the variable domains in which it consists 
of 15 amino acid and specifically designed to bridge the 3.5 nm gap between 
carboxy-terminus of the VH chain and the amino terminus of the VL chain 
(Huston et al., 1988 and Whitlow et al., 1991).  
 
In the early 90’s, McCafferty and coworkers (McCafferty et al., 1990) had 
developed one successful approach that relies on a phage-display system in 
which the fragments of antibodies (scFvs) are expressed as fusion proteins on 
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the minor coat protein (pIII) of the filamentous phage. In phage display 
system, an antigen is immobilized and a collection of binding proteins are 
displayed on the phage, together with the g3p as a fusion protein (Winter et 
al., 1994). All these systems share the principle of a relation between genotype 
(the Ig genes) and phenotype (antigen-binding). Therefore, the genetic 
information of the displayed protein is contained within the phage DNA in the 
same phage particle and thus, physically connected to the expressed protein. 
By using the polymerase chain reaction (PCR), both immunoglobulin variable 
(VH and VL) regions genes are first amplified from hybridomas or spleen cells 
followed by assembling into scFv fragment via a flexible linker, and expressed 
on the surface of the filamentous phages (phagebodies). In the selection 
procedure, so-called biopanning, the non-binding phage will be removed by 
washing while the remaining phages are used to infect E. coli for their 
amplification. The biopanning step can be repeated to reduce the number of 
clones to be assayed as well as to select clones with the highest affinity. It has 
also been proven by a number of researchers that extra rounds of panning 
could increase the selection efficiency of specific binding affinity clones 
(Maranhão and Brígido, 2000).  
 
ScFv antibodies produced from phage display can be genetically fused to the 
marker proteins, such as fluorescent proteins (Didier et al., 2008) or alkaline 
phosphatase (Mousli et al., 2007). These bifunctional proteins having both 
antigen-binding capacity and marker activity can be obtained from 
transformed bacteria and used for one-step immunodetection of biological 
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agents. Alternatively, antibody fragments could also be applied in the 
construction of immunotoxins, therapeutic gene delivery as well as anti-cancer 
intrabodies for therapeutic purposes. 
 
Because of these reasons, both recombinant antibody and phage display 
technologies have been exploited in the present study to produce an optimized 
reagent (scFv) starting from the mouse B-cell hybridoma cell line C3A8 (Ali 
et al., 1996), which generates a monoclonal antibody against MCF-7 breast 
cancer cells.  
 
Nowadays, breast cancer is the most common and frequent cause of cancer-
derived death in women (Gross, 2001). There are conventional therapies such 
as surgery, chemotherapy, radiotherapy, anti-estrogen therapy which are not 
able to eliminate occult cancer cells and therefore to prevent metastatic 
diseases, relapses, and bears the risk of side effects on non-tumor tissues 
(Chlebowski et al., 1999). Therefore, sensitive detection of residual cancer 
cells in breast tissue would have important therapeutic and prognostic 
implications. The potential targets for immunotherapy could achieved by 
identification of tumor-specific or associated antigens on the surface of breast 
cancer cells (Carter, 2001). The first promising approaches which have been 
published in immunotherapy involved the application of monoclonal 
antibodies, immunotoxins, bispecific antibodies or vaccination with tumor 
specific antigens (Ghadersohi et al., 2002 and Presta, 2002). Until now, 
recombinant antibody fragments have been proven promising in vitro as well 
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as in phase I and II clinical trials in certain types of cancer. In 2006, the US 
Food and Drug Administration (FDA) has approved a quadrivalent 
recombinant vaccine for the prevention of diseases caused by human 
papillomavirus types 6, 11, 16, and 18 in females aged 9 to 26 years and also a 
new indication for topotecan HCl injection, allowing its use in combination 
with cisplatin for the treatment of recurrent or persistent stage 4B cervical 
cancer.   
 
The MCF-7 breast cancer cells were chosen in this study since it is highly 
immunogenic and has distinct antigens that elicit antibodies specific for this 
type of cancer (Kida et al., 1975; Yuan et al., 1982 and Plessers et al., 1990). 
Several Mabs obtained from the hybrids between murine myeloma cells with 
spleen cells from mice immunized with MCF-7 cell line demonstrated a high 
degree of specificity for neoplastic as well as normal epithelial cells (Yuan et 
al., 1982). Therefore, these Mabs are very useful in diagnostic protocols 
against breast cancer. In addition, the changes on this murine antibody 
structure could then serve as immunotherapeutic reagents. 
C3A8 hybridoma is a fusion between the lymphocytes of Balb/c mice 
sensitized with the MCF-7 breast carcinoma cell line with Sp2 myeloma cells. 
It was proven to be very stable in generating murine Mabs (IgM) which could 
specifically react against MCF-7 and T47-D cell lines while weak cross 
reactivities was found with ovarian cancer, Cao-3 and pancreatic cancer 
PANC-1. But no reactivity was observed when Mab C3A8 was tested with 
tissues of normal breast and other organs (Ali et al., 1996). In consequence, 
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